Azione IMUX IMMUNIC, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Immunic, Inc.

Azioni

IMUX

US4525EP1011

Mercato chiuso - Nasdaq
Altri mercati azionari
 22:00:00 25/06/2024 		Variaz. 5gg Var. 1 gen.
1,08 USD -1,82% Grafico intraday di Immunic, Inc. 0,00% -28,00%
08/05 Transcript : Immunic, Inc., Q1 2024 Earnings Call, May 08, 2024
08/05 Immunic, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024 CI

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!
Registrazione 100% gratuita
Immunic Inc. CEO Daniel Vitt Highlights Advances in MS Treatment on World MS Day
Immunic to Participate in Industry and Scientific Conferences in June
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
Immunic chief medical officer discusses promising treatments to mark World IBD Day
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
Immunic : Q1 2024 News Release
Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Immunic: Q1 Earnings Snapshot
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
Immunic to Participate in Investor and Scientific Conferences in May
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
Immunic Announces Publication of Extended Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology Neuroimmunology and Neuroinflammation
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione IMUX
  4. Notizie Immunic, Inc.
  5. Altre lingue